N/A
N=200
Aprepitant for Post-operative Nausea
Postoperative Nausea
Bottom Line
View on ClinicalTrials.gov: NCT01020903 ↗Enrolled (actual)
200
Serious AEs
—
Results posted
Jun 2015
Primary outcome: Primary: Post-operative Nausea and Vomiting
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Aprepitant (Procedure); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwell Health
- Primary completion
- Nov 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Post-operative Nausea and Vomiting |
— | — |
Summary
Anesthesia, especially for laparoscopic surgery, can cause post-operative nausea and vomiting. Most patients are given two drugs, decadron and ondansetron, to try to minimize this. This study is to determine if a new drug, aprepitant, would add any benefit in terms of post-op nausea prevention. All laparoscopic cholecystectomy study patients will receive decadron and ondansetron. Half the patients will receive aprepitant in addition. The other half will receive placebo. The study will be randomized and double-blind.
Eligibility Criteria
Inclusion Criteria
- Laparoscopic cholecystectomy patients.
- Must be able to swallow a pill.
Exclusion Criteria
- Liver failure,
- Age less than 18.
- Pregnancy, breast-feeding.
- Pre-op vomiting.
- Allergy to aprepitant.
- Need for post-op gastric drainage.
- Use of drugs that interact with aprepitant.
Data sourced from ClinicalTrials.gov (NCT01020903). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.